PharmaEssentia’s Besremi receives FDA approval for ET
The approval is based on data from the global Phase III SURPASS ET trial, demonstrating durable ELN responses and control.
Drug Development
Kazia closes oversubscribed offering to fund paxalisib’s clinical development
Teva Pharmaceuticals to acquire BioXcel assets for up to $125m
AusperBio raises $120m to progress hepatitis B therapies
FDA to review Kowa Pharmaceuticals’ NDA for glaucoma eye drop K-911
FDA grants RPDD to ReviR’s RTX-117 for CMT
ViiV Healthcare’s Tivicay PD gains FDA approval for paediatric HIV therapy
Jazz secures FDA approval for Ziihera in advanced HER2+ GEA
